Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States. Selarsdi, like Stelara, is approved for the ...

Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...

Teva Pharmaceutical Industries' Q4 2024 results ... is intended to treat up to 11 million patients in the US still dependent on single-dose albuterol for asthma with a dual agent beta-agonist ...

Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.